Teva Pharmaceutical Industries Ltd. (TEVA)
40.06
+1.08
(+2.78%)
USD |
NYSE |
Sep 21, 16:00
40.07
0.00 (0.00%)
After-Hours: 20:00
Teva Pharmaceutical Industries Net Income (Quarterly) : -585.89M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -585.89M |
| March 31, 2026 | 368.00M |
| December 31, 2025 | 483.00M |
| September 30, 2025 | 436.04M |
| June 30, 2025 | 288.06M |
| March 31, 2025 | 218.86M |
| December 31, 2024 | -277.19M |
| September 30, 2024 | -391.16M |
| June 30, 2024 | -870.59M |
| March 31, 2024 | -423.65M |
| December 31, 2023 | 471.02M |
| September 30, 2023 | 75.73M |
| June 30, 2023 | -895.31M |
| March 31, 2023 | -250.63M |
| December 31, 2022 | -1.330B |
| September 30, 2022 | 59.52M |
| June 30, 2022 | -256.94M |
| March 31, 2022 | -954.07M |
| December 31, 2021 | -151.69M |
| September 30, 2021 | 302.41M |
| June 30, 2021 | 221.81M |
| March 31, 2021 | 83.13M |
| December 31, 2020 | 164.32M |
| September 30, 2020 | -4.372B |
| June 30, 2020 | 53.49M |
| Date | Value |
|---|---|
| March 31, 2020 | 25.04M |
| December 31, 2019 | 76.23M |
| September 30, 2019 | -309.12M |
| June 30, 2019 | -670.25M |
| March 31, 2019 | -97.38M |
| December 31, 2018 | -3.221B |
| September 30, 2018 | -196.85M |
| June 30, 2018 | -164.64M |
| March 31, 2018 | 1.133B |
| December 31, 2017 | -11.78B |
| September 30, 2017 | 610.40M |
| June 30, 2017 | -6.037B |
| March 31, 2017 | 649.67M |
| December 31, 2016 | -971.50M |
| September 30, 2016 | 412.48M |
| June 30, 2016 | 242.26M |
| March 31, 2016 | 638.90M |
| December 31, 2015 | 498.41M |
| September 30, 2015 | 115.25M |
| June 30, 2015 | 544.01M |
| March 31, 2015 | 442.21M |
| December 31, 2014 | 688.40M |
| September 30, 2014 | 853.40M |
| June 30, 2014 | 747.07M |
| March 31, 2014 | 739.20M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.095B |
| Bristol Myers Squibb Co. | 3.316B |
| RedHill Biopharma Ltd. | -- |
| Johnson & Johnson | 5.534B |
| Merck & Co., Inc. | -1.337B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 4.221B |
| Total Expenses (Quarterly) | 4.807B |
| EPS Diluted (Quarterly) | -0.5029 |
| Enterprise Value | 58.63B |
| Gross Profit Margin (Quarterly) | 52.07% |
| Profit Margin (Quarterly) | -13.88% |
| Earnings Yield | 1.48% |
| Operating Earnings Yield | 6.99% |
| Normalized Earnings Yield | 3.962 |